Performance of PfHRP2-RDT for malaria diagnosis during the first year of life in a high malaria transmission area in Burkina Faso
Hamtandi Magloire Natama(Research Institute of Health Sciences), Anna Rosanas‐Urgell(Papua New Guinea Institute of Medical Research), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Pieter Guetens(Instituut voor Tropische Geneeskunde), Tiampan Edwig Traoré(Institut de Recherche en Sciences de la Santé), Hermann Sorgho(Institut de Recherche en Sciences de la Santé), Toussaint Rouamba(Institut de Recherche en Sciences de la Santé), Eduard Rovira-Vallbona(Instituut voor Tropische Geneeskunde), Maminata Coulibaly-Traoré(Institut de Recherche en Sciences de la Santé), Innocent Valéa(Institut de Recherche en Sciences de la Santé), M. Athanase Somé(Institut de Recherche en Sciences de la Santé), Serge Henri Zango(Centre Muraz)
Cited by 3
Related Papers
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345